FaDu In Vitro High-throughput Screening (HTS) Assay

This assay is to provide FaDu-based In Vitro High-throughput Screening (HTS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

FaDu

Human

FaDu is a cell line with epithelial morphology that was established in 1968 from a punch biopsy of a hypopharyngeal tumor removed from a 56-year-old, White, male patient with squamous cell carcinoma. This cell line is a suitable transfection host and has applications in cancer and immuno-oncology research.

Squamous Cell Carcinoma

Oncology

In Vitro High-throughput Screening (HTS) Assay

FaDu-cell based In Vitro High-throughput Screening (HTS) Assay

HTS is one of the modern technologies used in cancer drug discovery. This technique enables to screen or assay thousands of chemical compounds against a target of interest within a short period. HTS is also useful in screening different libraries such as synthetic compounds, combinatorial chemistry, peptides and genomic libraries and obtaining toxicological and pharmacokinetic data related to chemical compounds. HTS has gained much attention among scientists and industries as a large number of compounds prepared by chemical synthesis methods can be screened within a short period, which can reduce the cost of drug discovery and animal use. HTS consist of major steps such as identification of targets, preparation of reagents, management of test compounds, development of suitable assay procedures and screening.

High-throughput Screening, High Content Screening and Reporter Gene Assays